Merck KGaA extends biopharmaceuticals manufacturing footprint in China

Germany’s Merck KGaA has opened a biomanufacturing facility in Shanghai, called the BioReliance End-to-End Biodevelopment Center.

The center will provide a full range of process development capabilities and services, including cell line development, upstream and downstream process development and non-GMP clinical production.

In November 2016, Merck announced a 250 million euro ($300 million) production value chain investment in Nantong, China, to help produce pharmaceuticals on China’s Essential Drug List.